Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.

@article{Maase1991RecombinantII,
  title={Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.},
  author={Hans von der Maase and Poul Flemming Geertsen and Nicholas Thatcher and Claude Jasmin and Alain Mercatello and Sophie D Fossa and Michel Symann and Gerrit J. Stoter and G P Nagel and Lucien Israel},
  journal={European journal of cancer},
  year={1991},
  volume={27 12},
  pages={1583-9}
}
This multinational, multicentre study represents the introduction of recombinant interleukin-2 (rIL-2) in Europe. From December 1987 to June 1989, 57 eligible patients with metastatic renal cell cancer were treated with rIL-2 administered as continuous intravenous infusion. 8 out of 51 evaluable patients responded (16%), 2 complete remission (CR) and 6 partial remission (PR). 10 patients had no change (20%). The response duration for CR was 209 and 394+ days. The median response duration for PR… CONTINUE READING
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…